Market capitalization | $3.52b |
Enterprise Value | $3.21b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 169.53 |
EV/Sales (TTM) EV/Sales | 7.85 |
P/S ratio (TTM) P/S ratio | 8.61 |
P/B ratio (TTM) P/B ratio | 5.46 |
Revenue growth (TTM) Revenue growth | 27.81% |
Revenue (TTM) Revenue | $408.81m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Axonics Modulation Technologies, Inc. forecast:
10 Analysts have issued a Axonics Modulation Technologies, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 409 409 |
28%
28%
|
|
Gross Profit | 301 301 |
32%
32%
|
|
EBITDA | 9.02 9.02 |
264%
264%
|
EBIT (Operating Income) EBIT | -5.11 -5.11 |
72%
72%
|
Net Profit | -1.71 -1.71 |
95%
95%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Head office | United States |
CEO | Raymond Cohen |
Employees | 797 |
Founded | 2012 |
Website | www.axonics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.